Superpower Medical Leadership and Credentials: An Independent Review

What Is Superpower and How Does Its Medical Model Work?

Superpower positions itself as a "health concierge" that combines deep lab diagnostics with prescription access to GLP-1 agonists, peptides, and hormone optimization protocols. Members pay a recurring subscription fee and receive ongoing provider access, structured lab reviews, and individualized treatment plans.

The core model is not unusual in the current telehealth space. Platforms like Hims, Ro, and Found operate on similar subscription architectures. What distinguishes Superpower's marketing is its emphasis on "optimization" rather than disease treatment, which creates specific regulatory considerations around off-label prescribing and compounded drug sourcing.

The Subscription Concierge Model: What It Means Clinically

A subscription concierge structure means patients pay regardless of whether they use the service in a given month. Clinically, this can be a strength or a weakness. When provider access is genuinely continuous, it supports the kind of longitudinal monitoring that GLP-1 and peptide therapy requires. When it is a billing mechanism layered over asynchronous questionnaires, it may not meet the standard of care for prescribing controlled or closely monitored medications.

The FDA's guidance on telehealth prescribing and the Ryan Haight Online Pharmacy Consumer Protection Act set baseline requirements: a valid prescriber-patient relationship, a clinical evaluation, and state licensure in the patient's state of residence.

Lab Panel Scope

Superpower markets expansive baseline panels. From a clinical standpoint, baseline labs before initiating GLP-1 therapy are supported by evidence. The American Diabetes Association's 2024 Standards of Care recommend assessing HbA1c, renal function, and lipid status before prescribing semaglutide or tirzepatide. Whether Superpower's panel design aligns with these guidelines is something a prospective patient should ask the platform to document in writing.

Is Superpower Legit? Evaluating the Core Legitimacy Signals

"Superpower legit" is among the top search queries about this brand, which reflects consumer uncertainty about a category, not just a company. Four concrete signals determine whether any telehealth optimization platform is operating legally and safely.

Signal 1: Physician Licensure

Every prescribing physician must hold an active, unrestricted license in the state where the patient resides. The Federation of State Medical Boards (FSMB) maintains a directory of all state board contacts. Patients can verify any physician's license status in roughly 5 minutes through their state's online lookup tool.

Superpower should disclose the name, NPI number, and state licensure of the physician assigned to each patient's case. If that information is unavailable or obscured, that is a material red flag. Board certification, while not legally required to prescribe, signals additional clinical training. The American Board of Medical Specialties (ABMS) physician lookup tool allows independent verification of board certification status.

Signal 2: DEA Registration for Controlled Substances

Some peptides and hormone agents prescribed through optimization platforms fall under DEA scheduling. Testosterone, for example, is a Schedule III controlled substance under 21 U.S.C. § 812. Any physician prescribing testosterone through Superpower must hold an active DEA registration in the patient's state. The DEA Diversion Control Division provides a public registration verification tool.

Signal 3: Pharmacy Accreditation and FDA Standing

The FDA's 503A and 503B compounding pharmacy framework governs how compounded medications including peptides and off-brand GLP-1 agents may be legally dispensed. A 503A pharmacy compounds for individual patients based on a valid prescription. A 503B outsourcing facility may produce larger batches but must register with the FDA and comply with current Good Manufacturing Practice (cGMP) standards.

As of early 2025, the FDA has removed semaglutide and tirzepatide from its drug shortage list, which significantly restricts which compounders may legally continue producing these formulations. The FDA's current shortage database is publicly searchable. Any platform continuing to source compounded semaglutide or tirzepatide from pharmacies not meeting the 503B criteria after the shortage designation was lifted may be operating outside current FDA guidance.

Signal 4: LegitScript Certification

LegitScript is an FDA-recognized third-party verification service for online pharmacies and telehealth platforms. Its certification database is publicly searchable. Platforms that carry LegitScript certification have undergone review of prescribing practices, pharmacy sourcing, and legal compliance. As of the date of this review, prospective Superpower members should search the LegitScript database directly to confirm current certification status, as this can change.

Superpower's GLP-1 Protocols: Clinical Strength or Marketing Gloss?

GLP-1 receptor agonists are among the most rigorously studied drug classes of the past decade. In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) (Wilding et al., NEJM 2021). The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced up to 20.9% mean weight loss at 72 weeks (Jastreboff et al., NEJM 2022).

These are the approved, brand-name medications: Ozempic, Wegovy, Mounjaro, and Zepbound. Any telehealth platform offering a GLP-1 program must clarify whether it is prescribing branded, FDA-approved drugs or compounded versions, and if the latter, through which pharmacy and under what legal authority.

Dose Titration and Monitoring Requirements

The FDA-approved label for Wegovy (semaglutide 2.4 mg, Novo Nordisk) specifies a structured titration: 0.25 mg weekly for 4 weeks, escalating by 0.25 mg every 4 weeks to a maintenance dose of 2.4 mg. The FDA prescribing information also requires assessment for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN-2) before prescribing.

A platform that skips titration or omits thyroid cancer history screening in its intake questionnaire is not following the approved label. Patients should review Superpower's intake form for both of these elements before enrolling.

Cardiovascular Risk Documentation

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with established cardiovascular disease and overweight or obesity (Lincoff et al., NEJM 2023). This benefit is population-specific. An optimization platform whose prescribing protocol does not document cardiovascular history misses a clinically significant risk-stratification step.

Peptide Protocols: Regulatory Gray Zone or Legitimate Medicine?

Peptides are where the regulatory complexity increases sharply. Compounds like BPC-157, TB-500, and CJC-1295 are not FDA-approved for human use. The FDA has explicitly stated that several peptides previously sold by compounders are not eligible for compounding under 503A or 503B because they are not components of FDA-approved drugs.

Ipamorelin and CJC-1295 (with or without DAC) fall into a legally uncertain category. Prescribing physicians who offer these compounds must be able to articulate the specific legal basis under which they are doing so.

What Patients Should Ask

Before accepting a peptide prescription through Superpower or any similar platform, ask the following questions directly in writing.

First: is this peptide on the FDA's current list of bulk drug substances eligible for compounding under 503A or 503B? The FDA bulk drug substance list is public and searchable.

Second: which specific pharmacy will compound this peptide, and is that pharmacy registered with the FDA as a 503A or 503B facility?

Third: has the prescribing physician reviewed the relevant safety literature? For growth hormone secretagogues like ipamorelin, there are no large randomized controlled trials in non-GH-deficient adults. The evidence base is primarily animal data and small human studies.

Sermorelin: The Comparatively Cleaner Option

Sermorelin acetate is a synthetic analogue of growth hormone-releasing hormone (GHRH) that was previously FDA-approved (withdrawn for commercial reasons, not safety). It sits in a more defensible regulatory position than many newer peptides. A review of GH secretagogue pharmacology (Walker 2006, NEJM correspondence) provides context on the mechanism. A platform that distinguishes between sermorelin and less-documented peptides in its clinical protocols demonstrates more rigorous medical oversight than one that groups them together.

Medical Leadership: Who Is Actually Behind the Protocols?

The quality of a telehealth platform's medical leadership determines whether its protocols reflect current evidence or marketing aspirations. A rigorous medical leadership structure includes the following elements, which we use as an evaluation framework across all brand reviews in this series.

The HealthRX Telehealth Medical Credibility Framework (7 Criteria)

1. Named Chief Medical Officer with publicly verifiable board certification and state licensure.
2. A documented clinical advisory board with specialty-relevant credentials (endocrinology, internal medicine, obesity medicine).
3. Published or publicly stated clinical protocols that reference specific guideline sources (ADA, Endocrine Society, AACE).
4. A defined quality assurance process for reviewing prescribing decisions.
5. A complaint resolution pathway that does not require arbitration waiver at enrollment.
6. Transparent disclosure of which pharmacy fulfillment partners the platform uses.
7. A conflict-of-interest disclosure policy covering medical advisors who may hold equity or financial interests in the platform.

As of the date of this review, Superpower's public-facing materials do not clearly satisfy all seven criteria. Specifically, the pharmacy fulfillment partner(s) and conflict-of-interest disclosure for medical advisors are not prominently documented on the platform's website. Prospective members should request this information before enrolling.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Pharmacological treatment of obesity should be initiated and monitored by a clinician with expertise in obesity medicine, with regular follow-up at intervals appropriate to the medication and patient risk profile." This standard applies to any telehealth platform offering GLP-1 therapy, including Superpower.

Superpower Complaints: What the Public Record Shows

No telehealth platform operating at scale is complaint-free. The relevant question is the nature and pattern of complaints. Three public databases are worth reviewing.

Better Business Bureau (BBB)

The BBB profile for Superpower (search bbb.org directly for the most current data) may contain complaint narratives, response rates, and resolution records. Common complaint categories in the telehealth optimization space include billing disputes on subscription renewals, delays in prescription fulfillment, and difficulty reaching a physician for follow-up. A pattern of unresolved billing complaints is qualitatively different from a pattern of clinical safety complaints.

Consumer Financial Protection Bureau (CFPB)

The CFPB consumer complaint database captures financial disputes with health and wellness subscription companies. Recurring complaints about subscription cancellation difficulty or unauthorized charges are searchable by company name.

State Attorney General Offices

State AG offices in California, New York, and Texas have been active in pursuing telehealth platforms that make unsubstantiated health claims or use deceptive subscription practices. A search of the California AG's enforcement actions database and equivalents in the patient's state of residence may surface relevant findings.

As of the writing of this article, no publicly documented FDA warning letter or FTC enforcement action specifically naming Superpower has been identified through a search of the FDA Warning Letters database or the FTC Action database. This is a positive data point, not a comprehensive clearance.

How Superpower Compares to AACE and Endocrine Society Standards

The American Association of Clinical Endocrinology's 2023 Obesity Clinical Practice Guidelines and the Endocrine Society's framework both specify that optimization-oriented prescribing requires documented clinical indication, structured follow-up, and patient education on adverse effects.

For GLP-1 therapy specifically, AACE recommends HbA1c and fasting glucose at baseline, lipid panel, and kidney function tests before initiation. Monitoring at 4, 12, and 24 weeks post-initiation is also recommended. Any platform that conducts a single intake questionnaire and ships medication without structured follow-up does not meet this standard.

The Obesity Medicine Association similarly requires documentation of weight-related comorbidities and risk factors. Patients using a platform like Superpower should confirm in writing what the follow-up schedule is, who conducts it, and how labs are reviewed at each interval.

What a Clinically Sound Superpower Membership Should Include

A well-run concierge telehealth membership for GLP-1 and peptide therapy should include these minimum clinical elements, based on current guideline consensus.

Baseline assessment: Complete metabolic panel, HbA1c, fasting lipids, TSH, CBC, and a structured history for contraindications specific to the medications being prescribed.

Prescribing documentation: Written clinical rationale in the patient's record, with the specific indication, chosen medication, starting dose, titration schedule, and monitoring plan.

Follow-up cadence: At minimum, a 4-week check-in after initiation (phone, video, or structured questionnaire reviewed by a physician), followed by 12-week and 24-week reviews with repeat relevant labs.

Adverse effect guidance: Written patient education on GLP-1 adverse effects (nausea, vomiting, gastroparesis risk, pancreatitis warning signs) provided before the first dose, as required by the FDA-approved labeling for semaglutide (FDA label, Wegovy).

Pharmacy transparency: The dispensing pharmacy's name, NABP number, and FDA registration status provided before fulfillment.

If Superpower provides all of these elements, it meets the clinical floor. If any are absent, patients carry additional risk that the platform's subscription fee does not offset.